# US 2012/0252099 A1 · Immunogenic minicells and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252099 A1
- Document ID: US20120252099A1
- Status: Published application
- Kind: A1
- Application number: 13/412,559
- Filed: 2012-03-05
- Published: 2012-10-04
- Earliest claimed: 2001-05-24
- Assignees: Vaxiion Therapeutics, Inc.
- Inventors: Roger A. Sabbadini; Neil Berkley; Mark W. Surber; Matthew J. Giacalone
- Web page: https://patentgrep.com/patent/US20120252099A1

## CPC

- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- A61K 39/12: Viral antigens
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C40B 40/02: Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- G01N 33/543: with an insoluble carrier for immobilising immunochemicals
- G01N 33/5432: {Liposomes or microcapsules}
- G01N 33/60: involving radioactive labelled substances
- A61K 2039/53: {DNA (RNA) vaccination}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.

## Claims

### Claim 1

A fully intact eubacterial minicell for use in generating an immunogenic response in an animal, comprising a plasmid having an open reading frame encoding a viral antigen of interest, and a eukaryotic expression sequence operably linked to said open reading frame, such that said antigen of interest is expressed in said animal.

### Claim 2 (depends on 1)

The minicell of claim 1, wherein said eukaryotic expression sequence comprises a CMV promoter.

### Claim 3 (depends on 1)

The minicell of claim 1, wherein said eukaryotic expression sequence comprises a stress-inducible promoter.

### Claim 4 (depends on 1)

The minicell of claim 1, wherein said open reading frame is from the genome of a virus.

### Claim 5 (depends on 4)

The minicell of claim 4, where said virus is selected from the group consisting of HIV, smallpox virus, Hepatitis A, Hepatitis B, Hepatitis C, influenza virus, varicella zoster virus, Herpes Simplex Virus, adenovirus, rhinovirus, rinderpest, exhovirus, rotavirus, respiratory syncitial virus, papilloma virus, papova virus, cytomegalovirus, echinovirus, arbovirus, hantavirus, coxsackie virus, mumps virus, measles virus, polio virus, and rubella virus.

### Claim 6 (depends on 1)

The minicell of claim 1, further comprising a prokaryotic expression sequence operably linked to said open reading frame, such that said antigen of interest is capable expressed in the minicell and the animal.

### Claim 7 (depends on 6)

The minicell of claim 6, wherein said antigen of interest expressed in the minicell is displayed on the surface of the minicell.
